Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abraham, 1988, Effects of NMDA receptor/channel antagonists CPP and MK-801 on hippocampal field potentials and long-term potentiation in anasthetized rats, Brain Res., 462, 40, 10.1016/0006-8993(88)90582-3
Alessandri-Haber, 2006, A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators, J. Neurosci., 26, 3864, 10.1523/JNEUROSCI.5385-05.2006
Andine, 1991, Intra- and extracellular changes of amino acids in the cerebral cortex of the neonatal rat during hypoxic-ischemia, Dev. Brain Res., 64, 115, 10.1016/0165-3806(91)90214-4
Andrasi, 2000, Disturbances of magnesium concentrations in various brain areas in Alzheimer's disease, Magnes. Res., 13, 189
Aracava, Y., Pereira, E.F., Maelicke, A., Albuquerque, E.X., 2004. Memantine at clinically relevant concentrations blocks more potently α7 nicotinic than NMDA receptors: implications for treatment of Alzheimer's disease, P1–416.
Aracava, 2005, Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than N-methyl-d-aspartate receptors in rat hippocampal neurons, J. Pharmacol. Exp. Ther., 312, 1195, 10.1124/jpet.104.077172
Avenet, 1997, Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1a/NR2A and NR1a/NR2B receptors expressed in Xenopus oocytes, Neurosci. Lett., 223, 133, 10.1016/S0304-3940(97)13422-X
Bachurin, 2001, Neuroprotective and cognition-enhancing properties of MK-801 flexible analogs. Structure–activity relationships, Ann. N. Y. Acad. Sci., 939, 219, 10.1111/j.1749-6632.2001.tb03629.x
Bakchine, S., Pascual-Gangnant L., Loft, H., 2005. Results of a randomised, placebo-controlled 6-month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. ADIS title: memantine: therapeutic use, Alzheimer's disease in patients with mild to moderate illness 2087.
Barber, 2002, The effects of memantine on memory formation for passive avoidance learning in day – old chicks, Soc. Neurosci. Abst., 28, 684.6
Bardgett, 2005, Magnesium deficiency impairs fear conditioning in mice, Brain Res., 1038, 100, 10.1016/j.brainres.2005.01.020
Barghorn, 2005, Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease, J. Neurochem., 95, 834, 10.1111/j.1471-4159.2005.03407.x
Barnes, 1996, Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats, Eur. J. Neurosci., 8, 565, 10.1111/j.1460-9568.1996.tb01241.x
Beal, 1995, Aging, energy, and oxidative stress in neurodegenerative diseases, Ann. Neurol, 38, 357, 10.1002/ana.410380304
Beal, 2000, Energetics in the pathogenesis of neurodegenerative diseases, Trends Neurosci., 23, 298, 10.1016/S0166-2236(00)01584-8
Benveniste, 1984, Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis, J. Neurochem., 43, 1369, 10.1111/j.1471-4159.1984.tb05396.x
Birks, 2006, Cholinesterase inhibitors for Alzheimer's disease, Cochrane Database Syst. Rev., CD005593, 10.1002/14651858.CD005593
Black, 1996, Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2, Eur. J. Pharmacol., 317, 377, 10.1016/S0014-2999(96)00730-3
Blanchard, 1993, A mitochondrial DNA deletion in normally aging and in Alzheimer brain tissue, Neuroreport, 4, 799, 10.1097/00001756-199306000-00051
Blanchard, 2002, Mechanism of membrane depolarization caused by the Alzheimer Abeta1–42 peptide, Biochem. Biophys. Res. Commun., 293, 1197, 10.1016/S0006-291X(02)00346-7
Blanpied, 1997, Trapping channel block of NMDA-activated responses by amantadine and memantine, J. Neurophysiol., 77, 309, 10.1152/jn.1997.77.1.309
Blass, 2000, Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise, Ann. N. Y. Acad. Sci., 903, 204, 10.1111/j.1749-6632.2000.tb06370.x
Bormann, 1989, Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels, Eur. J. Pharmacol., 166, 591, 10.1016/0014-2999(89)90385-3
Bowen, 1992, Beta-amyloid increased neuronal susceptibility to injury by glucose deprivation, Neuroreport, 3, 733
Bresink, 1996, Effects of memantine on recombinant rat NMDA receptors expressed in HEK-293 cells, Br. J. Pharmacol., 119, 195, 10.1111/j.1476-5381.1996.tb15971.x
Bresink, 1995, Different binding affinities of NMDA receptor channel blockers in various brain regions – indication of NMDA receptor heterogeneity, Neuropharmacology, 34, 533, 10.1016/0028-3908(95)00017-Z
Brewer, 2000, Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons, J. Neurochem., 74, 1968, 10.1046/j.1471-4159.2000.0741968.x
Brorson, 1995, The ca2+ influx induced by beta-amyloid peptide 25–35 in cultured hippocampal neurons results from network excitation, J. Neurobiol., 26, 325, 10.1002/neu.480260305
Buisson, 1992, Striatal protection induced by lesioning the substantia nigra of rats subjected to focal ischemia, J. Neurochem., 59, 1153, 10.1111/j.1471-4159.1992.tb08358.x
Buisson, 1998, Open-channel blockers at the human alpha 4 beta 2 neuronal nicotinic acetylcholine receptor, Mol. Pharmacol., 53, 555, 10.1124/mol.53.3.555
Bullock, 2006, Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date, Alzheimer Dis. Assoc. Disord., 20, 23, 10.1097/01.wad.0000201847.29836.a5
Burns, 2006, Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology, J. Psychopharmacol., 20, 732, 10.1177/0269881106068299
Carvalho, 2006, Thiamine deficiency decreases glutamate uptake in the prefrontal cortex and impairs spatial memory performance in a water maze test, Pharmacol. Biochem. Behav., 83, 481, 10.1016/j.pbb.2006.03.004
Chen, 1997, Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism, J. Physiol. (Lond.), 499, 27, 10.1113/jphysiol.1997.sp021909
Chen, 1992, Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine – therapeutic advantage against NMDA receptor-mediated neurotoxicity, J. Neurosci., 12, 4427, 10.1523/JNEUROSCI.12-11-04427.1992
Chen, 1998, Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation, Neuroscience, 86, 1121, 10.1016/S0306-4522(98)00163-8
Chen, 2002, Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus, Neurobiol. Learn. Mem., 77, 354, 10.1006/nlme.2001.4034
Clark, 1992, Unsuspected morbid hypermagnesemia in elderly patients, Am. J. Nephrol., 12, 336, 10.1159/000168469
Clements, 1992, The time course of glutamate in the synaptic cleft, Science, 258, 1498, 10.1126/science.1359647
Coan, 1987, Characterization of an N-methyl-d-aspartate receptor component of synaptic transmission in rat hippocampal slice, Neuroscience, 22, 1, 10.1016/0306-4522(87)90192-8
Coan, 1989, Low-frequence activation of the NMDA receptor system can prevent the induction of LTP, Neurosci. Lett., 105, 205, 10.1016/0304-3940(89)90038-4
Cohn, 1994, Lead exposure potentiates the effects of NMDA on repeated learning, Neurotoxicol. Teratol., 16, 455, 10.1016/0892-0362(94)90123-6
Collingridge, 1995, Memories of NMDA receptors and LTP, Trends Neurosci., 18, 54, 10.1016/0166-2236(95)93868-X
Copani, 1991, B-amyloid increases neuronal susceptibility to injury by glucose deprivation, Neuroreport, 2, 763, 10.1097/00001756-199112000-00008
Costello, 2004, The role of c-Jun N-terminal kinase in the A beta-mediated impairment of LTP and regulation of synaptic transmission in the hippocampus, Neuropharmacology, 46, 655, 10.1016/j.neuropharm.2003.11.016
Crawford, 1996, Alzheimer's disease risk factors as related to cerebral blood flow, Med. Hypotheses, 46, 367, 10.1016/S0306-9877(96)90189-9
Creeley, 2006, Low doses of memantine disrupt memory in adult rats, J. Neurosci., 26, 3923, 10.1523/JNEUROSCI.4883-05.2006
Cummings, 2006, Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment, Neurology, 67, 57, 10.1212/01.wnl.0000223333.42368.f1
Dantoine, 2006, Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment, Int. J. Clin. Pract., 60, 110, 10.1111/j.1368-5031.2005.00769.x
Danysz, 1994, Glutamate antagonists have different effects on spontaneous locomotor activity in rats, Pharmacol. Biochem. Behav., 48, 111, 10.1016/0091-3057(94)90506-1
Danysz, 2003, The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease preclinical evidence, Int. J. Geriatr. Psychiatry, 18, S23, 10.1002/gps.938
Danysz, 1997, Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents – preclinical studies, Neurosci. Biobehav. Rev., 21, 455, 10.1016/S0149-7634(96)00037-1
Danysz, 2000, Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease – an unified glutamatergic hypothesis on the mechanism of action, Neurotox. Res., 2, 85, 10.1007/BF03033787
Danysz, 1995, Modulation of learning processes by ionotropic glutamate receptor ligands, Behav. Pharmacol., 6, 455, 10.1097/00008877-199508000-00007
Davies, 1988, Differences in results from in vivo and in vitro studies on the use-dependency of N-methyl-aspartate antagonism by MK-801 and other phencyclidine receptor ligands, Eur. J. Pharmacol., 145, 141, 10.1016/0014-2999(88)90225-7
De Felice, 2007, A beta oligomers induce neuronal oxidative stress through an NMDA receptor-dependent mechanism that is blocked by the Alzheimer's drug memantine, J. Biol. Chem., 282, 11590, 10.1074/jbc.M607483200
De Felice, F.G., Wu, D., Lambert, M.P., Fernandez, S.J., Velasco, P.T., Lacor, P.N., Bigio, E.H., Jerecic, J., Acton, P.J., Shughrue, P.J., Chen-Dodson, E., Kinney, G.G., Klein, W.L., 2007b. Alzheimer's disease-type neuronal Tau hyperphosphorylation induced by Abeta oligomers. Neurobiol. Aging.
Delatorre, 1994, Impaired brain microcirculation may trigger Alzheimer's disease, Neurosci. Biobehav. Rev., 18, 397, 10.1016/0149-7634(94)90052-3
Dickey, 2005, Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice, BMC Neurosci., 6, 7, 10.1186/1471-2202-6-7
Ditzler, 1991, Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial, Arzneimittelforschung, 41, 773
Doody, 2004, Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease, Dement. Geriatr. Cogn. Disord., 18, 227, 10.1159/000079833
Doody, 2005, Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease, Ann. Neurol., 58, 49
Durlach, 1990, Magnesium depletion and pathogenesis of Alzheimer's disease, Magnes. Res., 3, 217
van Dyck, 2006, A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil, Am. J. Geriatr. Psychiatry, 14, 428, 10.1097/01.JGP.0000203151.17311.38
Elgoyhen, 2001, Alpha 10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells, Proc. Natl. Acad. Sci. U.S.A., 98, 3501, 10.1073/pnas.051622798
Emerit, 2004, Neurodegenerative diseases and oxidative stress, Biomed. Pharmacother., 58, 39, 10.1016/j.biopha.2003.11.004
Enz, 2004, Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain, Neuropharmacology, 47, 408, 10.1016/j.neuropharm.2004.04.009
Ferris, 2003, Evaluation of memantine for the treatment of Alzheimer's disease, Expert Opin. Pharmacother., 4, 2305, 10.1517/14656566.4.12.2305
Floden, 2005, Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors, J. Neurosci., 25, 2566, 10.1523/JNEUROSCI.4998-04.2005
Franceschi, 1995, Correlations between cognitive impairment, middle cerebral artery flow velocity and cortical glucose metabolism in the early phase of Alzheimer's disease, Dementia, 6, 32
Frankiewicz, 1999, Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices, Neuropharmacology, 38, 1253, 10.1016/S0028-3908(99)00060-X
Frankiewicz, 1996, Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices, Br. J. Pharmacol., 117, 689, 10.1111/j.1476-5381.1996.tb15245.x
Freir, 2001, Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo, J. Neurophysiol., 85, 708, 10.1152/jn.2001.85.2.708
Fung, 1995, Hypermagnesemia. Elderly over-the-counter drug users at risk, Arch. Fam. Med., 4, 718, 10.1001/archfami.4.8.718
Furukawa, 1998, Secreted amyloid precursor protein alpha selectively suppresses N-methyl-d-aspartate currents in hippocampal neurons: involvement of cyclic GMP, Neuroscience, 83, 429, 10.1016/S0306-4522(97)00398-9
Gauthier, 2005, Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies, Int. J. Geriatr. Psychiatry, 20, 459, 10.1002/gps.1341
Gerzon, 1963, The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N′-adamantylureas, J. Med. Chem., 6, 760, 10.1021/jm00342a029
Gilling, 2007, Agonist concentration-dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine, Neuropharmacology, 53, 415, 10.1016/j.neuropharm.2007.05.022
Glick, 1990, Dementias: the role of magnesium deficiency and an hypothesis concerning the pathogenesis of Alzheimer's disease, Med. Hypotheses, 31, 211, 10.1016/0306-9877(90)90095-V
Globus, 1991, Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine, and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat, J. Neurochem., 57, 470, 10.1111/j.1471-4159.1991.tb03775.x
Globus, 1991, Excitotoxic index – a biochemical marker of selective vulnerability, Neurosci. Lett., 127, 39, 10.1016/0304-3940(91)90889-2
Golde, 2006, Disease modifying therapy for AD?, J. Neurochem., 99, 689, 10.1111/j.1471-4159.2006.04211.x
Goto, 1993, Positron emission tomographic (PET) studies in dementia, J. Neurol. Sci., 114, 1, 10.1016/0022-510X(93)90040-6
Grant, 1996, Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists, Neuropharmacology, 35, 1709, 10.1016/S0028-3908(96)00147-5
Greenamyre, 1991, Neuronal bioenergetic defects, excitotoxicity and Alzheimer's disease – use it and lose it, Neurobiol. Aging, 12, 334, 10.1016/0197-4580(91)90012-9
Grimwood, 1996, Modulation of 45Ca2+ influx into cells stably expressing recombinant human NMDA receptors by ligands acting at distinct recognition sites, J. Neurochem., 66, 2589, 10.1046/j.1471-4159.1996.66062589.x
Hallak, 1998, Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain, Magnes. Res., 11, 117
Harris, 1996, Amyloid beta peptide (25–35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures, J. Neurochem., 67, 277, 10.1046/j.1471-4159.1996.67010277.x
Hartmann, 2003, Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy, Int. Clin. Psychopharmacol., 18, 81, 10.1097/00004850-200303000-00003
Hattori, 1998, CI-ATPase and Na+/K(+)-ATPase activities in Alzheimer's disease brains, Neurosci. Lett., 254, 141, 10.1016/S0304-3940(98)00654-5
Henneberry, 1989, The role of neuronal energy in the neurotoxicity of excitatory amino acids, Neurobiol. Aging, 10, 611, 10.1016/0197-4580(89)90149-8
Herrero, 1994, Memantine selectively depresses NMDA receptor-mediated responses of rat spinal neurones in vivo, Neurosci. Lett., 165, 37, 10.1016/0304-3940(94)90703-X
Herron, 1986, Frequency-dependent involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism, Nature, 322, 265, 10.1038/322265a0
Hesselink, 1999, Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study, Pharm. Res., 16, 637, 10.1023/A:1018856020583
Hesselink, 1999, Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration, Behav. Pharmacol., 10, 85, 10.1097/00008877-199902000-00008
Hesselink, 1999, The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-d-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies, J. Pharmacol. Exp. Ther., 290, 543
Hirai, 1996, The glycine binding site of the N-methyl-d-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular m3–m4 loop region, Proc. Natl. Acad. Sci. U.S.A., 93, 6031, 10.1073/pnas.93.12.6031
Honegger, 1993, Evidence for lysosomotropism of memantine in cultured human cells – cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission, Pharmacol. Toxicol., 73, 202, 10.1111/j.1600-0773.1993.tb01564.x
Howland, 2006, Stress-induced spatial memory disruption depends on long-term depression in the hippocampus, Soc. Neurosci. Abst., 32, 266.16
Hoyer, 1996, Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease, Acta Neurol. Scand., 93, 18, 10.1111/j.1600-0404.1996.tb05868.x
Hoyer, 2000, Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update, Exp. Gerontol., 35, 1363, 10.1016/S0531-5565(00)00156-X
Hoyer, 1989, Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type, J. Neural Transm. – Gen. Sect., 75, 227, 10.1007/BF01258634
Hoyer, 1991, Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type – a cross-sectional comparison against advanced late-onset and incipient early-onset cases, J. Neural Transm., 3, 1, 10.1007/BF02251132
Hutchin, 1995, A mitochondrial DNA clone is associated with increased risk for Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A., 92, 6892, 10.1073/pnas.92.15.6892
Izumi, 1992, Low concentrations of N-methyl-d-aspartate inhibit the induction of long-term potentiation in rat hippocampal slices, Neurosci. Lett., 137, 245, 10.1016/0304-3940(92)90414-3
Johnson, 2006, Mechanism of action of memantine, Curr. Opin. Pharmacol., 6, 61, 10.1016/j.coph.2005.09.007
Jones, 1989, Systemically administered N-methyl-d-aspartate interferes with acquisition of passive avoidance response in rats, Pharmacol. Biochem. Behav., 34, 181, 10.1016/0091-3057(89)90370-5
Jones, 2001, The in vivo significance of the varied channel blocking properties of uncompetitive NMDA receptor antagonists, Neuropharmacology, 41, 50, 10.1016/S0028-3908(01)00041-7
Kairane, 2002, Regulation of the frontocortical sodium pump by Na+ in Alzheimer's disease: difference from the age-matched control but similarity to the rat model, FEBS Lett., 531, 241, 10.1016/S0014-5793(02)03510-X
Katagiri, 2001, Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction, Eur. J. Neurosci., 14, 547, 10.1046/j.0953-816x.2001.01664.x
Katz, 2004, Developmental regulation of nicotinic synapses on cochlear inner hair cells, J. Neurosci., 24, 7814, 10.1523/JNEUROSCI.2102-04.2004
Keller, 1997, Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal, J. Neurochem., 69, 273, 10.1046/j.1471-4159.1997.69010273.x
Kennedy, 1995, Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease, Neurosci. Lett., 186, 17, 10.1016/0304-3940(95)11270-7
Kew, 1998, State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist, Br. J. Pharmacol., 123, 463, 10.1038/sj.bjp.0701634
Kim, 2001, Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo, J. Neurosci., 21, 1327, 10.1523/JNEUROSCI.21-04-01327.2001
Klein, 2004, Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease, Neurobiol. Aging, 25, 569, 10.1016/j.neurobiolaging.2004.02.010
Kornhuber, 1989, [3H]MK-801 binding sites in post-mortem human frontal cortex, Eur. J. Pharmacol., 162, 483, 10.1016/0014-2999(89)90339-7
Kornhuber, 1995, Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man, Neurosci. Lett., 195, 137, 10.1016/0304-3940(95)11785-U
Kornhuber, 1997, Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy, Biol. Psychiatry, 41, 135, 10.1016/S0006-3223(96)00047-9
Kotermanski, 2004, Partial trapping of memantine by NMDA receptors, Soc. Neurosci. Abst., 30, 731.7
Kwong, 2006, The role of mitochondria in inherited neurodegenerative diseases, J. Neurochem., 97, 1659, 10.1111/j.1471-4159.2006.03990.x
Lacor, 2007, Aβ oligomers-induced aberrations in synapse composition, shape and density provide a molecular basis for loss of connectivity in Alzheimer's disease, J. Neurosci., 27, 796, 10.1523/JNEUROSCI.3501-06.2007
Ladner, 1999, Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations, Exp. Neurol., 158, 451, 10.1006/exnr.1999.7116
Lambert, 1998, Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins, Proc. Natl. Acad. Sci. U.S.A, 95, 6448, 10.1073/pnas.95.11.6448
Lanctot, 2003, Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis, CMAJ, 169, 557
Landfield, 1984, Chronically elevating plasma Mg2+ improves hippocampal frequency potentiation and reversal learning in aged and young rats, Brain Res., 322, 167, 10.1016/0006-8993(84)91199-5
Lanthorn, 2000, Differences in degree of trapping between AR-R15896 and other uncompetitive NMDA receptor antagonists, Amino Acids, 19, 173, 10.1007/s007260070046
Laube, 1997, Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit, Neuron, 18, 493, 10.1016/S0896-6273(00)81249-0
Lesne, 2005, NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production, J. Neurosci., 25, 9367, 10.1523/JNEUROSCI.0849-05.2005
Lesne, 2006, A specific amyloid-beta protein assembly in the brain impairs memory, Nature, 440, 352, 10.1038/nature04533
Li, 1998, Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical, Eur. J. Neurosci., 10, 1704, 10.1046/j.1460-9568.1998.00169.x
Lipton, 2005, The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism, Curr. Alzheimer Res., 2, 155, 10.2174/1567205053585846
Lipton, 2006, Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond, Nat. Rev. Drug Discov., 5, 160, 10.1038/nrd1958
Lipton, 2004, Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine, Cell Death Differ., 11, 18, 10.1038/sj.cdd.4401344
Luhrs, L.B., Banerjee, P.K., LeFerla, F.M., 2006. Memantine reverses cognitive deficits in transgenic mice with both plaques and tangles, P1–001.
Lukoyanov, 2001, Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol, Neurosci. Lett., 309, 45, 10.1016/S0304-3940(01)02037-7
Maskell, 2003, Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-d-aspartate receptors, Br. J. Pharmacol., 140, 1313, 10.1038/sj.bjp.0705559
Masliah, 1998, Amyloid protein precursor stimulates excitatory amino acid transport. Implications for roles in neuroprotection and pathogenesis, J. Biol. Chem., 273, 12548, 10.1074/jbc.273.20.12548
Mattson, 1993, β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease, Trends Neurosci., 16, 409, 10.1016/0166-2236(93)90009-B
McShane, 2006, Memantine for dementia, Cochrane Database Syst. Rev., CD003154, 10.1002/14651858.CD003154.pub5
Mecocci, 1994, Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease, Ann. Neurol., 36, 747, 10.1002/ana.410360510
Mielke, 1992, Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type, Neurobiol. Aging, 13, 93, 10.1016/0197-4580(92)90015-P
Miguel-Hidalgo, 2005, Memantine inhibits the expression of caspase-8 and improves learning in rats injected with β-amyloid (Aβ1–40), Soc. Neurosci. Abst., 31, 1019.5
Minkeviciene, 2004, Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease, J. Pharmacol. Exp. Ther., 311, 677, 10.1124/jpet.104.071027
Misztal, 1996, Learning deficits induced by chronic intraventricular infusion of quinolinic acid – protection by MK-801 and memantine, Eur. J. Pharmacol., 296, 1, 10.1016/0014-2999(95)00682-6
Mitani, 1992, Selective vulnerability of hippocampal CA1 neurons cannot be explained in terms of an increase in glutamate concentration during ischemia in the gerbil: brain microdialysis study, Neuroscience, 48, 307, 10.1016/0306-4522(92)90492-K
Molinuevo, 2003, Memantine, Neurologia, 18, 255
Monyer, 1994, Developmental and regional expression in the rat brain and functional properties of four NMDA receptors, Neuron, 12, 529, 10.1016/0896-6273(94)90210-0
Morris, 1986, Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5, Nature, 319, 774, 10.1038/319774a0
Nakagami, 2002, Glutamate exacerbates amyloid beta1–42-induced impairment of long-term potentiation in rat hippocampal slices, Jpn J. Pharmacol., 88, 223, 10.1254/jjp.88.223
Nakamura, 2006, Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801, Eur. J. Pharmacol., 548, 115, 10.1016/j.ejphar.2006.07.049
Nankai, 1998, The pharmacology of native N-methyl-d-aspartate receptor subtypes: different receptors control the release of different striatal and spinal transmitters, Prog. Neuropsychopharmacol. Biol. Psychiatry, 22, 35, 10.1016/S0278-5846(97)00180-2
Noda, 1999, Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide, Neuroscience, 92, 1465, 10.1016/S0306-4522(99)00036-6
Nomura, 2005, Mechanism of impairment of long-term potentiation by amyloid beta is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons, Neurosci. Lett., 391, 1, 10.1016/j.neulet.2005.08.024
Novelli, 1988, Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced, Brain Res., 451, 205, 10.1016/0006-8993(88)90765-2
Nowak, 1984, Magnesium gates glutamate-activated channels in mouse central neurons, Nature, 307, 462, 10.1038/307462a0
Nyakas, C., Szabó, R., Penke, B., Banerjee, P., Luiten, P.G.M., 2006. Memantine rescues cholinergic neurons from the neurotoxic effects of β-amyloid (Aβ1–42) P4–305.
Oliver, 2001, Memantine inhibits efferent cholinergic transmission in the cochlea by blocking heteromeric alpha9/alpha10 acetylcholine receptors of outer hair cells, Pfluegers Arch. Eur. J. Physiol., 441, R203
Orgogozo, 2002, Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300), Stroke, 33, 1834, 10.1161/01.STR.0000020094.08790.49
Ozturk, 2006, Magnesium supplementation in the treatment of dementia patients, Med. Hypotheses, 67, 1223, 10.1016/j.mehy.2006.04.047
ParpuraGill, 1997, The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes, Brain Res., 754, 65, 10.1016/S0006-8993(97)00043-7
Parsons, 1998, Glutamate in CNS disorders as a target for drug development: an update, Drug News Perspect., 11, 523, 10.1358/dnp.1998.11.9.863689
Parsons, 1999, Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization, Neuropharmacology, 38, 85, 10.1016/S0028-3908(98)00161-0
Parsons, 1999, Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist – a review of preclinical data, Neuropharmacology, 38, 735, 10.1016/S0028-3908(99)00019-2
Parsons, C.G., Gilling, K.E., Jatzke, C. Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes. Eur. J. Pharmacol., submitted for publication.
Parsons, 1993, Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan), Neuropharmacology, 32, 1337, 10.1016/0028-3908(93)90029-3
Parsons, 1998, Budipine is a low affinity, N-methyl-d-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones, Neuropharmacology, 37, 719, 10.1016/S0028-3908(98)00059-8
Parsons, 1996, Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine, Eur. J. Neurosci., 8, 446, 10.1111/j.1460-9568.1996.tb01228.x
Parsons, 1995, Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo, Neuropharmacology, 34, 1239, 10.1016/0028-3908(95)00092-K
Periclou, 2004, Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil, Ann. Pharmacother., 38, 1389, 10.1345/aph.1D638
Peskind, 2006, Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial, Am. J. Geriatr. Psychiatry, 14, 704, 10.1097/01.JGP.0000224350.82719.83
Porter, 1995, Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential, J. Neurochem., 64, 614, 10.1046/j.1471-4159.1995.64020614.x
Puzzo, 2006, Fibrillar beta-amyloid impairs the late phase of long term potentiation, Curr. Alzheimer Res., 3, 179, 10.2174/156720506777632871
Quack, 1995, Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover, J. Neural Transm. Suppl., 46, 97
Rammes, 2001, The NMDA receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes also antagonise 5-HT3 receptor currents in HEK-293 and N1E-115 cells in a non-competitive manner, Neurosci. Lett., 306, 81, 10.1016/S0304-3940(01)01872-9
Rammsayer, 2001, Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans, Learn. Mem., 8, 20, 10.1101/lm.33701
Raschetti, 2005, A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease, Eur. J. Clin. Pharmacol., 61, 361, 10.1007/s00228-005-0946-1
Raymond, 2003, NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus, Brain Res., 968, 263, 10.1016/S0006-8993(03)02269-8
Reisberg, 2003, Memantine in moderate-to-severe Alzheimer's disease, N. Engl. J. Med., 348, 1333, 10.1056/NEJMoa013128
Rogawski, 1993, Therapeutic potential of excitatory amino acid antagonists – channel blockers and 2,3-benzodiazepines, Trends Pharmacol. Sci., 14, 325, 10.1016/0165-6147(93)90005-5
Rogawski, 2003, The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease, CNS Drug Rev., 9, 275, 10.1111/j.1527-3458.2003.tb00254.x
Rogawski, 1991, Anticonvulsant activity of the low-affinity uncompetitive N-methyl-d-aspartate antagonist (+/−)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo<a,d>cyclohepten-5, 10-imine (ADCI) – comparison with the structural analogs dizocilpine (mK-801) and carbamazepine, J. Pharmacol. Exp. Ther., 259, 30
Rosen, 1984, A new rating scale for Alzheimer's disease, Am. J. Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356
Rowan, 2003, Synaptic plasticity in animal models of early Alzheimer's disease, Philos. Trans. R. Soc. Lond. B Biol. Sci., 358, 821, 10.1098/rstb.2002.1240
Rowan, 2004, Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity, Exp. Gerontol., 39, 1661, 10.1016/j.exger.2004.06.020
Rowan, 2005, Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies, Biochem. Soc. Trans., 33, 563, 10.1042/BST0330563
Saxton, 1993, The severe impairment battery, 1
Schmitt, 1996, Severe impairment battery: a potential measure for AD clinical trials, 419
Schmitt, 2002, Measuring cognition in advanced Alzheimer's disease for clinical trials, Stoffler AdJ. Neural Transm. Suppl., 62, 135, 10.1007/978-3-7091-6139-5_14
Schmitt, 2006, Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis, Alzheimer Dis. Assoc. Disord., 20, 255, 10.1097/01.wad.0000213860.35355.d4
Schugens, 1997, The NMDA antagonist memantine impairs classical eyeblink conditioning in humans, Neurosci. Lett., 224, 57, 10.1016/S0304-3940(97)13452-8
Si, 2004, Effects of NMDA receptor antagonists on olfactory learning and memory in the honeybee (Apis mellifera), Pharmacol. Biochem. Behav., 77, 191, 10.1016/j.pbb.2003.09.023
Simpson, 1994, Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with alzheimers disease, Ann. Neurol., 35, 546, 10.1002/ana.410350507
Sobolevsky, 1998, Two blocking sites of amino-adamantane derivatives in open N-methyl-D-aspartate channels, Biophys. J., 74, 1305, 10.1016/S0006-3495(98)77844-0
Sobolevsky, 1998, Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons, J. Physiol. (Lond.), 512, 47, 10.1111/j.1469-7793.1998.047bf.x
Spanagel, 1994, Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat – a pharmacokinetic microdialysis study, Eur. J. Pharmacol., 262, 21, 10.1016/0014-2999(94)90023-X
Sucher, 1995, Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-l) in the rodent brain, J. Neurosci., 15, 6509, 10.1523/JNEUROSCI.15-10-06509.1995
Takeda, 2006, A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease, Int. J. Geriatr. Psychiatry, 21, 17, 10.1002/gps.1402
Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA, 291, 317, 10.1001/jama.291.3.317
Thompson, 2004, The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease, Expert Opin. Drug Saf., 3, 425, 10.1517/14740338.3.5.425
de la Torre, 2000, Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide, Brain. Res. Rev., 34, 119, 10.1016/S0165-0173(00)00043-6
Townsend, 2006, Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers, J. Physiol., 572, 477, 10.1113/jphysiol.2005.103754
Van Dam, 2005, Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model, Psychopharmacology (Berl.), 180, 177, 10.1007/s00213-004-2132-z
Van Dam, 2006, Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model, Eur. Neuropsychopharmacol., 16, 59, 10.1016/j.euroneuro.2005.06.005
Vignini, 2006, Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites, Neurobiol. Aging, 28, 987, 10.1016/j.neurobiolaging.2006.05.010
Walsh, 2002, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo, Nature, 416, 535, 10.1038/416535a
Walsh, 2004, Deciphering the molecular basis of memory failure in Alzheimer's disease, Neuron, 44, 181, 10.1016/j.neuron.2004.09.010
Walsh, 2005, Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation, J. Neurosci., 25, 2455, 10.1523/JNEUROSCI.4391-04.2005
Wang, 2002, Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus, Brain Res., 924, 133, 10.1016/S0006-8993(01)03058-X
Wang, 2004, Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide, J. Neurosci., 24, 6049, 10.1523/JNEUROSCI.0233-04.2004
Wang, 2004, Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5, J. Neurosci., 24, 3370, 10.1523/JNEUROSCI.1633-03.2004
Wang, 2005, Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor, Eur. J. Neurosci., 22, 2827, 10.1111/j.1460-9568.2005.04457.x
Wary, 1999, Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by 31P-NMRS and ion selective electrodes, Br. J. Clin. Pharmacol., 48, 655, 10.1046/j.1365-2125.1999.00063.x
Wenk, 1994, Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat, Brain Res., 655, 7, 10.1016/0006-8993(94)91590-3
Wenk, 1996, The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis, Neuroreport, 7, 1453, 10.1097/00001756-199606170-00001
Wenk, 2006, Potential role of NMDA receptors as executors of neurodegeneration resulting from diverse insults focus on memantine, Behav. Pharmacol., 17, 411, 10.1097/00008877-200609000-00007
Wesemann, 1982, Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat, Arzneimittelforschung, 32, 1241
Wesemann, 1982, Distribution of Memantine in brain, Liver, and blood of the rat, Arzneimittelforschung, 32, 1243
Wesemann, 1980, Distribution of metabolism of the potential anti-parkinson drug memantine in the human, J. Neural Transm. Suppl., 16, 143
Wilcock, 2002, A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500), Int. Clin. Psychopharmacol., 17, 297, 10.1097/00004850-200211000-00005
Willard, 2000, The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition, Exp. Brain Res., 134, 58, 10.1007/s002210000446
Winblad, 1998, Clinical improvement in a placebo-controlled trial with memantine in care-dependent patients with severe dementia, Neurobiol. Aging, 19, S303
Wu, 1995, beta-amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus, Neuroreport, 6, 2409, 10.1097/00001756-199511270-00031
Xiong, 2004, Activation of NR1a/NR2B receptors by soluble factors from APP-stimulated monocyte-derived macrophages: implications for the pathogenesis of Alzheimer's disease, Neurobiol. Aging, 25, 905, 10.1016/j.neurobiolaging.2003.09.007
Yamada, 2005, Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats, Behav. Brain Res., 162, 191, 10.1016/j.bbr.2005.02.036
Yang, 1999, Ca2+ and Mg2+ selectively induce aggregates of PHF-Tau but not normal human Tau, J. Neurosci. Res., 55, 36, 10.1002/(SICI)1097-4547(19990101)55:1<36::AID-JNR5>3.0.CO;2-E
Ye, 2004, Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-d-aspartate (NMDA) versus non-NMDA receptor/channel activation, Neurosci. Lett., 366, 320, 10.1016/j.neulet.2004.05.060
Ye, 1999, Suppressive action produced by beta-amyloid peptide fragment 31–35 on long-term potentiation in rat hippocampus is N-methyl-d-aspartate receptor-independent: it's offset by (−)huperzine A, Neurosci. Lett., 275, 187, 10.1016/S0304-3940(99)00795-8
Zajaczkowski, 1997, Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP, Neuropharmacology, 36, 961, 10.1016/S0028-3908(97)00070-1
Zajaczkowski, 2000, Behavioural evaluation of long-term neurotoxic effects of NMDA receptor antagonists, Neurotox. Res., 1, 299, 10.1007/BF03033259
Zajaczkowski, 1996, Discriminative stimulus effects of the NMDA receptor antagonists MK-801 and CGP 37849 in rats, Pharmacol. Biochem. Behav., 55, 163, 10.1016/0091-3057(95)02290-2
Zajaczkowski, 1996, Infusion of (+)-MK-801 and memantine – contrasting effects on radial maze learning in rats with entorhinal cortex lesion, Eur. J. Pharmacol., 296, 239, 10.1016/0014-2999(95)00716-4
Zakharova, 2005, Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats, Psychopharmacology, 179, 128, 10.1007/s00213-004-2067-4